April 3, 2017 / 4:29 PM / 8 months ago

BRIEF-Versartis announces three year Somavaratan data

April 3 (Reuters) - Versartis Inc:

* Three-year Vertical/Vista study results support selection of 3.5 mg/kg twice-monthly dose regimen for phase 3 Velocity trial underway Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below